Updated EU Guide On Unique Identifiers May Impact Drug Distribution Strategies Post Brexit
The European Commission's updated guidance on the unique identifiers that are required under the Falsified Medicines Directive contains new information on several areas. It clarifies that the “decommissioned status” of an exported medicine that is brought back into the EU from a third country cannot be reversed and that such medicines should be fitted with a fresh identifier.
You may also be interested in...
The EU guideline on complying with the requirement to affix safety features on medicine packs has been updated to address specific aspects of parallel trade, such as re-sealing of medicine packs that are legally opened to replace patient information leaflets.
The EU’s new medicines verification system, which is due to come into operation in February 2019, is experiencing delays, partly as a result of differences in member state approaches to the implementation of safety features on product packs. The European association representing generic and biosimilar firms has warned that any delays in setting up the system could lead to product shortages.
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.